Letolizumab
Letolizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is currently under development by Biocon Biologics and Viatris.
History[edit]
Letolizumab was originally developed by Biocon Biologics, a subsidiary of Biocon, an Indian biopharmaceutical company. In 2020, Biocon Biologics partnered with Viatris, a global healthcare company, to further develop and commercialize the drug.
Mechanism of Action[edit]
Letolizumab is a monoclonal antibody that targets the CD6 protein, a surface molecule present on T cells. By binding to CD6, letolizumab inhibits the activation and proliferation of T cells, thereby reducing the immune response that contributes to autoimmune diseases.
Clinical Trials[edit]
Letolizumab has undergone several clinical trials to evaluate its safety and efficacy in treating autoimmune diseases. These trials have shown promising results, with letolizumab demonstrating a good safety profile and potential efficacy in reducing symptoms of autoimmune diseases.
Potential Uses[edit]
Letolizumab is being investigated for use in a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Further clinical trials are needed to confirm its efficacy and safety in these conditions.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
